Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: A 19-year experience from an established australian hepatobiliary unit

Journal of Gastrointestinal Surgery

Volumn 14, Issue 7, 2010, Pages 1128-1138

  Saxena, Akshat ^a   Chua, Terence C ^a   Sarkar, Anik ^a   Chu, Francis ^a   Morris, David L ^b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cholangiocarcinoma; Hepatectomy; Intrahepatic; Recurrence; Survival

Indexed keywords

TUMOR ANTIGEN;

ARTICLE; AUSTRALIA; BILE DUCT CARCINOMA; BILE DUCT TUMOR; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTRAHEPATIC BILE DUCT; LIVER RESECTION; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; EPIDEMIOLOGY;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; AUSTRALIA; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE;

EID: 77953709236     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-010-1203-1     Document Type: Article

References (25)

1. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004; 66: 167-179.
2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24(2): 115-125.
3. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006; 15(6): 1198-1203.
4. Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; Epub.
5. Kopek N, Holt MI, Hansen AT, Hoyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; Epub.
6. Jang JS, Lim HY, Hwang IG, et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 2010; 65(4): 641-647.
7. Jin Hyoung K, Hyun-Ki Y, Kyu-Bo S, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma. Cancer 2008; 113(7): 1614-1622.
8. Lang H, Sotiropoulos GC, Sgourakis G, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208(2): 218-228.
9. Lang H, Sotiropoulos GC, Fruhauf Nr, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC) When is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005; 241: 134-143.
10. Shen WF, Zhong W, Xu F, et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol 2009; 15(47): 5976-5982.
11. Zhou XD, Tang ZY, Fan J, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5, 829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135: 1073-1080.
12. Yedibela S, Demir R, Zhang W, et al. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients. Ann Surg Oncol 2009; 16(2): 404-412.
13. Japan LCSGo. 2003.
14. Sobin LH, Wittekind CH. TNM classification of malignant tumours, 6th ed. West Sussex: John Wiley & Sons, 2002.
15. Kavolius J, Fong Y, Blumgart LH. Surgical resection of metastatic liver tumors. Surg Oncol Clin N Am 1996; 5(2): 337-352.
16. Nakagohri T, Kinoshita T, Konishi M, et al. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg 2008; 32: 2675-2680.
17. Saiura A, Yamamoto J, Kokudo N, et al. Intrahepatic cholangiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. Am J Surg 2010; Epub.
18. de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008; 248(4): 626-637.
19. Yoshihiro N, Masayuki Y, Iwao I, et al. Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the International Union Against Cancer TNM staging system for primary liver carcinoma. Cancer 1998; 83(9): 1923-1929.
20. Uenishi T, Kubo S, Yamazaki O, et al. Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg 2008; 15(4): 417-422.
21. Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009; 16: 3048-3056.
22. Tamandl D, Kaczirek K, Gruenberger B, et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg 2009; 96: 919-925.
23. Uenishi T, Kubo S, Yamazaki O, et al. Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg 2008; 15: 417-422.
24. Manousos MK, Sasan R, Ilias PG, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008; 143(3): 366-374.
25. Eric TS, Nandita M, Mengye G, James MM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008; 72(5): 1495-1501.